Stocks · Health care · Pharmaceutical Preparations

Enliven Therapeutics, Inc.

ELVN Clue Score23
United States Fiscal year ends December CIK 0001672619 Results filed 5 Nov 2026

What the insiders did Net selling

By person

10 insiders · 80 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Orbimed Advisors LLC entity
10% owner
—
$51.68M (6)
−$51.68M
6,555,102
8.95%
$252.16M
−14.8%
Mika K Derynck
Director
—
$9.56M (1) scheduled
−$9.56M
0
0.0000%
$0.00
—
Helen Louise Collins
Chief Medical Officer
—
$5.58M (25) scheduled
−$5.58M
25,000
0.0341%
$961.71K
—
Joseph P Lyssikatos
Chief Scientific Officer
—
$4.52M (10) scheduled
−$4.52M
758,938
1.04%
$29.20M
−25.2%
Benjamin Hohl
Chief Financial Officer
—
$1.76M (15) scheduled
−$1.76M
38,000
0.0519%
$1.46M
—
Anish Patel
Chief Operating Officer
—
$1.61M (6) scheduled
−$1.61M
235,011
0.3207%
$9.04M
−31.5%
Lori Anne Kunkel
Director
—
$850.25K (5) scheduled
−$850.25K
52,925
0.0722%
$2.04M
+15.2%
J. Scott Garland
Director
—
$606.72K (1) scheduled
−$606.72K
0
0.0000%
$0.00
—
Richard A. Heyman
Director
—
$413.38K (6) scheduled
−$413.38K
22,647
0.0309%
$871.19K
−42.0%
Samuel Kintz
President and CEO
—
$272.74K (1) scheduled
−$272.74K
890,392
1.22%
$34.25M
−11.1%